lebrikizumab
Sponsor ELI Lilly & CO · listed as LLY
lebrikizumab is a drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2027 (month precision, medium confidence), tied to trial NCT05735483. That trial is in Phase 3 and currently enrolling by invitation, studying Atopic Dermatitis. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for lebrikizumab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06280716 | Phase 3 | Active, not recruiting | 2025-09-25 | Experimental | Eli Lilly and Company | Atopic Dermatitis |
| NCT05559359 | Phase 3 | Active, not recruiting | 2026-01-14 | Experimental | Eli Lilly and Company | Atopic Dermatitis; Eczema |
| NCT06526182 | Phase 3 | Active, not recruiting | 2027-04-25 | Experimental | Almirall, S.A. | Dermatitis, Atopic; Eczema |
| NCT05735483 catalyst | Phase 3 | Enrolling by invitation | 2027-12 | Experimental | Eli Lilly and Company | Atopic Dermatitis; Eczema |
| NCT07542483 | Phase 3 | Recruiting | 2028-08 | Experimental | Almirall, S.A. | Nummular Eczema |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More LLY catalysts